公开(公告)号：US20220155303A1

公开(公告)日：2022-05-19

申请号：US17528578

申请日：2021-11-17

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Tae Woo KIM ,  Hyo Jung LEE

IPC: G01N33/574 ,  G01N33/50

Abstract: Disclosed herein are a method and a biomarker for predicting efficacy and prognosis of or resistance to an immunotherapy. The use of the biomarkers (TCTP, EGFR, AKT, MCL1, and/or CXCL10) of the present disclosure allows the prediction of resistance to or prognosis of a cancer immunotherapeutic agent and the selection of a therapy guaranteeing therapeutic benefit, thereby finding advantageous applications in treating cancers or tumors resistant to cancer immunotherapeutic agents.

公开(公告)号：US20160090435A1

公开(公告)日：2016-03-31

申请号：US14962183

申请日：2015-12-08

Applicant: Samsung Display Co., Ltd. ,  Sogang University Research Foundation ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Min Hyuck KANG ,  Su Mi LEE ,  Myung Im KIM ,  Tae Woo KIM ,  Seung-Won PARK ,  Xie LEI ,  Na Na KANG ,  Bong-Jin MOON ,  Joona BANG ,  Sang Hoon WOO ,  Jin Yeong LEE ,  Hyun Jung JUNG ,  June HUH

IPC: C08F299/02

CPC classification number: C08F299/024 ,  C08F293/00 ,  C08G61/08 ,  C08G2261/1424 ,  C08G2261/1426 ,  C08G2261/3324 ,  C08G2261/418 ,  C08G2261/74

Abstract: A block copolymer is provided. The block copolymer according to an exemplary embodiment includes a first block represented by Chemical Formula 1 and a second block represented by Chemical Formula 2: wherein COM1 and COM2 are independently selected from a polystyrene moiety, polymethylmethacrylate moiety, polyethylene oxide moiety, polyvinylpyridine moiety, polydimethylsiloxane moiety, polyferrocenyldimethylsilane moiety, and polyisoprene moiety, R1 is hydrogen or an alkyl group with 1 to 10 carbon atoms, Ph is a phenyl group, a is 1 to 50, R2 is hydrogen or an alkyl group with 1 to 10 carbon atoms, and b is 1 to 50.

Abstract translation: 提供嵌段共聚物。 根据示例性实施方案的嵌段共聚物包括由化学式1表示的第一嵌段和由化学式2表示的第二嵌段：其中COM1和COM2独立地选自聚苯乙烯部分，聚甲基丙烯酸甲酯部分，聚环氧乙烷部分，聚乙烯基吡啶部分，聚二甲基硅氧烷 部分，聚二茂铁基二甲基硅烷部分和聚异戊二烯部分，R1为氢或碳原子数为1〜10的烷基，Ph为苯基，a为1〜50，R2为氢或碳原子数1〜10的烷基， b为1〜50。

公开(公告)号：US20140197132A1

公开(公告)日：2014-07-17

申请号：US14086182

申请日：2013-11-21

Applicant: Samsung Display Co., Ltd. ,  Sogang University Research Foundation ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Min Hyuck KANG ,  Su Mi LEE ,  Myung Im KIM ,  Tae Woo KIM ,  Seung-Won PARK ,  Xie LEI ,  Na Na KANG ,  Bong-Jin MOON ,  Joona BANG ,  Sang Hoon WOO ,  Jin Yeong LEE ,  Hyun Jung JUNG ,  June HUH

IPC: C08F32/06

CPC classification number: C08F299/024 ,  C08F293/00 ,  C08G61/08 ,  C08G2261/1424 ,  C08G2261/1426 ,  C08G2261/3324 ,  C08G2261/418 ,  C08G2261/74

Abstract: A block copolymer is provided. The block copolymer according to an exemplary embodiment includes a first block represented by Chemical Formula 1 and a second block represented by Chemical Formula 2: wherein COM1 and COM2 are independently selected from a polystyrene moiety, polymethylmethacrylate moiety, polyethylene oxide moiety, polyvinylpyridine moiety, polydimethylsiloxane moiety, polyferrocenyldimethylsilane moiety, and polyisoprene moiety, R1 is hydrogen or an alkyl group with 1 to 10 carbon atoms, Ph is a phenyl group, a is 1 to 50, R2 is hydrogen or an alkyl group with 1 to 10 carbon atoms, and b is 1 to 50.

Abstract translation: 提供嵌段共聚物。 根据示例性实施方案的嵌段共聚物包括由化学式1表示的第一嵌段和由化学式2表示的第二嵌段：其中COM1和COM2独立地选自聚苯乙烯部分，聚甲基丙烯酸甲酯部分，聚环氧乙烷部分，聚乙烯基吡啶部分，聚二甲基硅氧烷 部分，聚二茂铁基二甲基硅烷部分和聚异戊二烯部分，R1为氢或碳原子数为1〜10的烷基，Ph为苯基，a为1〜50，R2为氢或碳原子数1〜10的烷基， b为1〜50。

公开(公告)号：US20240426825A1

公开(公告)日：2024-12-26

申请号：US18825663

申请日：2024-09-05

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Tae Woo KIM ,  Hyo Jung LEE

IPC: G01N33/574 ,  G01N33/50

Abstract: Disclosed herein are a method and a biomarker for predicting efficacy and prognosis of or resistance to an immunotherapy. The use of the biomarkers (TCTP, EGFR, AKT, MCL1, and/or CXCL10) of the present disclosure allows the prediction of resistance to or prognosis of a cancer immunotherapeutic agent and the selection of a therapy guaranteeing therapeutic benefit, thereby finding advantageous applications in treating cancers or tumors resistant to cancer immunotherapeutic agents.

公开(公告)号：US20200223914A1

公开(公告)日：2020-07-16

申请号：US16626625

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd. ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Bongcheol KIM ,  Eun Bee CHO ,  Dong Sik KIM ,  Jae-Keun LEE ,  Soon-gu KWON ,  Jae Young SEONG ,  Juwon SHIM ,  Tae Woo KIM ,  Shin-hyuk KANG

IPC: C07K16/24 ,  A61P35/00 ,  C07K16/30

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.